Article ID Journal Published Year Pages File Type
8680579 Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 18 Pages PDF
Abstract
The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. The trials include a wide range of clinical trial populations, many mechanisms of action, and require a substantial number of clinical trial participants. Biomarkers are increasingly used in patient identification and as outcome measures, particularly in trials of DMTs.
Related Topics
Life Sciences Neuroscience Neurology
Authors
, , , , ,